210 related articles for article (PubMed ID: 34864494)
1. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
[TBL] [Abstract][Full Text] [Related]
2. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
3. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
Petrelli F; Barni S
Breast Cancer Res Treat; 2013 Nov; 142(2):227-35. PubMed ID: 24177758
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
5. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
[TBL] [Abstract][Full Text] [Related]
6. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
7. Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands.
Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Duijm LE; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2015 May; 22(5):1471-8. PubMed ID: 25323475
[TBL] [Abstract][Full Text] [Related]
8. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of lobular carcinoma from a national screening program: a retrospective analysis.
Sharma SD; Barry M; O'Reilly EA; Kell MR
Eur J Surg Oncol; 2015 Jan; 41(1):79-85. PubMed ID: 25441933
[TBL] [Abstract][Full Text] [Related]
10. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.
Volders JH; Haloua MH; Krekel NM; Negenborn VL; Barbé E; Sietses C; Jóźwiak K; Meijer S; van den Tol MP;
Eur J Surg Oncol; 2016 Jul; 42(7):986-93. PubMed ID: 27211343
[TBL] [Abstract][Full Text] [Related]
12. Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma.
Wanis ML; Wong JA; Rodriguez S; Wong JM; Jabo B; Ashok A; Lum SS; Solomon NL; Reeves ME; Garberoglio CA; Senthil M
Am Surg; 2013 Oct; 79(10):1119-22. PubMed ID: 24160812
[TBL] [Abstract][Full Text] [Related]
13. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
Mathieu MC; Rouzier R; Llombart-Cussac A; Sideris L; Koscielny S; Travagli JP; Contesso G; Delaloge S; Spielmann M
Eur J Cancer; 2004 Feb; 40(3):342-51. PubMed ID: 14746851
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
15. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
[TBL] [Abstract][Full Text] [Related]
16. Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
Mamtani A; Grabenstetter A; Sevilimedu V; Morrow M; Gemignani ML
Breast Cancer Res Treat; 2023 Jan; 197(2):417-423. PubMed ID: 36394689
[TBL] [Abstract][Full Text] [Related]
17. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
18. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
Ramalingam K; Clelland E; Rothschild H; Mujir F; Record H; Kaur M; Mukhtar RA
Ann Surg Oncol; 2023 Nov; 30(12):7099-7106. PubMed ID: 37561345
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
20. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
